I-Hemab Therapeutics, inkampani ye-biotechnology ethuthukisa izindlela zokwelapha zesizukulwane esilandelayo ngenxa yezinkinga ezingathi sína, ezinganakiwe ukopha kanye ne-thrombosis, namuhla yethule ikhandidethi yayo eholayo, i-HMB-001, inoveli ye-bispecific antibody enamandla okwelapha i-Glanzmann Thrombasthenia (GT) nezinye izifo ezingavamile ukopha. . Le nkampani yethule idatha ethembisayo ye-preclinical ku-HMB-001 ngesikhathi se-European Association for Haemophilia and Allied Disorders Virtual Congress ka-2022, eyayibanjwe ngoFebhuwari 2-4, 2022.
Engqungqutheleni, i-Hemab yagqamisa idatha evela ezifundweni ezihlola indlela yokusebenza ye-HMB-001 ezinkawini ezingama-cynomolgus kanye nokuhlolwa kwama-platelet avela ezigulini ze-GT. I-in vivo elawulwa ngaphansi kwe-subcutaneously imithamo eyodwa ye-HMB-001 ibonise ukunqwabelana okuncike kumthamo we-endogenous factor VIIa (FVIIa), nokuqina komphumela osekela umthamo wamasonto onke ukuya kanye ngenyanga. I-TLT-1, iphrotheni etholakala ebusweni bamaplatelet acushiwe endaweni yokulimala, kwaqinisekiswa ukuthi ikhona kumaplatelet e-GT futhi i-HMB-001 yatholwa ithuthukisa kakhulu i-FVIIa egqugquzelwe i-ex vivo GT platelet aggregation ku-TLT-1-encike. indlela.
Ihlanganisa ukunqwabelana kanye namandla omsebenzi, i-HMB-001 iletha umsebenzi we-FVIIa engapheli kumazinga abhekwa njengokwelashwa ngempumelelo ngokusekelwe kokuhlangenwe nakho komtholampilo nge-recombinant factor VIIa (rFVIIa). I-HMB-001 iyi-bispecific antibody, enengalo eyodwa ebopha i-FVIIa kakade ekhona egazini lesiguli (i-endogenous) kanti enye ingalo ebopha i-TLT-1 ekhona ebusweni be-platelet ecushiwe; lokhu ngempumelelo, futhi ngokuqondile, kubuthela i-FVIIa ngaphezulu kweplatelet ecushiwe. Ingalo ebopha i-FVIIa ivimbela umzimba ukuthi ungayephuli, okwandisa ukugxila okutholakalayo egazini kuya ezingeni elisha lesimo esiqinile phakathi nezinsuku ezimbalwa. Ukubophezela okumaphakathi kwe-FVIIa kusho ukuthi isasebenza futhi ingadlala indima ekwenzeni amapulaki ane-hemostatic. Ngokuqondisa ama-platelet acushiwe endaweni yokulimala kwemithambo ene-FVIIa ephezulu (nge-TLT-1), umzimba ukhiqiza amabhulokhi okwakha azwakala kahle ngokwesakhiwo ukuze akhe amapulaki e-hemostatic anempilo.
Ngokubambisana ne-Haemnet, esebenzisana nabasebenzi bezempilo, iziguli, imiphakathi, nabanye ababambiqhaza ukwenza ngcono izimpilo zabantu abanezinkinga zokopha ngocwaningo, imfundo, nokuxhumana, i-Hemab iqala izifundo zomlando wemvelo weziguli ezine-GT ekuqaleni kuka-2022 ukuze zibe ngcono. baqonde imvamisa nezinhlobo zokopha, inani labantu abathintekayo, ukuhlukahluka kwezifo, nomthelela empilweni neminyaka yokuphila.
I-Hemab izoqala uhlolo lomtholampilo lweSigaba 1/2 ezigulini ezine-GT ngasekupheleni kuka-2022 ukuze ihlole ukuphepha nokusebenza ngempumelelo kwe-HMB-001, ekuqaleni ngokubambisana nenkampani ehola phambili yocwaningo lwemitholampilo yeSigaba 1 sase-UK, i-Richmond Pharmacology Ltd.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- Ngokubambisana ne-Haemnet, esebenzisana nabasebenzi bezempilo, iziguli, imiphakathi, nabanye ababambiqhaza ukwenza ngcono izimpilo zabantu abanezinkinga zokopha ngocwaningo, imfundo, nokuxhumana, i-Hemab iqala izifundo zomlando wemvelo weziguli ezine-GT ekuqaleni kuka-2022 ukuze zibe ngcono. baqonde imvamisa nezinhlobo zokopha, inani labantu abathintekayo, ukuhlukahluka kwezifo, nomthelela empilweni neminyaka yokuphila.
- TLT-1, a protein found on the surface of activated platelets at the site of injury, was confirmed to be present on GT platelets and HMB-001 was found to substantially improve FVIIa facilitated ex vivo GT platelet aggregation in a TLT-1-dependent manner.
- HMB-001 is a bispecific antibody, with one arm binding FVIIa already present in the patient’s bloodstream (endogenous) and the other arm binding TLT-1 present on the surface of the activated platelet.
